{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:07:04Z","timestamp":1789762024401,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006280","name":"Urology Care Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021763","name":"American Urological Association","doi-asserted-by":"publisher","award":["IRG 85-001-25"],"award-info":[{"award-number":["IRG 85-001-25"]}],"id":[{"id":"10.13039\/100021763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.017","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:52:42Z","timestamp":1786391562000},"page":"728-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Yair","family":"Lotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrishab","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Neema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-1290","authenticated-orcid":false,"given":"Trevor J.","family":"Royce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswesh","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.urolonc.2026.07.017_bib0001","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2017.82","article-title":"Landmarks in the treatment of muscle-invasive bladder cancer","volume":"14","author":"Lobo","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.017_bib0002","first-page":"81","article-title":"Disparities in bladder cancer","volume":"30","author":"Jacobs","year":"2012","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.017_bib0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.017_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.urolonc.2026.07.017_bib0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.urolonc.2026.07.017_bib0006","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2026.07.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.07.017_bib0008","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2022.40.6_suppl.518","article-title":"A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer","volume":"40","author":"Ikram","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.07.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16531","article-title":"Patterns and predictors of treatment in muscle-invasive bladder cancer (MIBC): a real-world study","volume":"39","author":"Lu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.017_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","article-title":"Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.07.017_bib0011","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.urolonc.2019.04.006","article-title":"Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer","volume":"37","author":"Macleod","year":"2019","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.07.017_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after Bacillus Calmette-Gu\u00e9rin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.017_bib0013","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.017_bib0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","article-title":"Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations","volume":"5","author":"Hensley","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"24","key":"10.1016\/j.urolonc.2026.07.017_bib0015","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.017_bib0016","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.017_bib0017","first-page":"192","article-title":"Predicting response to intravesical Bacillus Calmette-Gu\u00e9rin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12-center cohort","volume":"213","author":"Lotan","year":"2025","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.017_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2025.05.035","volume":"88","author":"Chang","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.017_bib0019","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JU.0000000000004541","article-title":"AI biomarkers predict poor efficacy of BCG rechallenge in previously BCG-treated non-muscle invasive bladder cancer","volume":"214","author":"Lotan","year":"2025","journal-title":"J Urol"},{"issue":"7492","key":"10.1016\/j.urolonc.2026.07.017_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.017_bib0021","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"issue":"30","key":"10.1016\/j.urolonc.2026.07.017_bib0022","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.07.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.017_bib0024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2025.09.4164","article-title":"Histopathology-only artificial intelligence for prostate cancer: towards accessible risk stratification","volume":"89","author":"Riaz","year":"2026","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.017_bib0025","doi-asserted-by":"crossref","first-page":"572.e21","DOI":"10.1016\/j.urolonc.2019.04.027","article-title":"The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer","volume":"37","author":"Waingankar","year":"2019","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.07.017_bib0026","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.07.017_bib0027","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.urolonc.2023.01.001","article-title":"Bladder preservation after neoadjuvant therapy \u2013 2021 IBCN updates part 1","volume":"41","author":"Hensley","year":"2023","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.017_bib0028","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.017_bib0029","doi-asserted-by":"crossref","first-page":"TPS4615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","article-title":"A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)","volume":"40","author":"Iyer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.017_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.017_bib0031","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JU.0000000000002261","article-title":"Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy","volume":"207","author":"Lotan","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.017_bib0032","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41746-025-01560-y","article-title":"Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning","volume":"8","author":"Bai","year":"2025","journal-title":"NPJ Digit Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.017_bib0033","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/cancers18020249","article-title":"Impact of computational histology AI biomarkers on clinical management decisions in non-muscle invasive bladder cancer: a multi-center real-world study","volume":"18","author":"Packiam","year":"2026","journal-title":"Cancers"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:20:41Z","timestamp":1789759241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926006010"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}